MA-HARVEY-PERFORMANCE
15.7.2024 15:00:31 CEST | Business Wire | Press release
Harvey Performance Company (“Harvey Performance” or the “company”), a leading provider of specialized cutting tools for precision machining applications, today announced the acquisition of ATA. Harvey Performance serves the market through industry-leading brands Harvey Tool, Helical Solutions, Micro 100, Titan USA, CoreHog, and Valor Holemaking. ATA is an Ireland-based precision engineering multinational and the parent company of the Karnasch, SGSPRO, ATA Tools, Van Hoorn Carbide, Industrial Tooling Corporation (“ITC”), and Garryson brands.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240715286290/en/
“We couldn’t be more excited about welcoming ATA to the Harvey Performance family,” said Brian Lavelle, Chief Executive Officer of Harvey Performance Company. “This acquisition represents a milestone in the proud history of the company and further establishes our integrated, international business comprised of distinctive brands and product lines.”
Since its inception as a family business in 1963, ATA has remained steadfast in its dedication to manufacturing, supplying, and distributing tools of exceptional quality. Today, it boasts a product offering exceeding 25,000 precision industrial cutting tools which it supplies to leading manufacturing industries, including aerospace, power generation, electronics, and more. ATA –which is headquartered in Ireland and has additional operating locations in the United Kingdom, United States, Germany, The Netherlands, and Switzerland – engineers, manufactures, and distributes its products globally from its seven manufacturing facilities, worldwide.
“We were immediately impressed by ATA, its global team and tremendous collection of brands,” Lavelle said. “Like all Harvey Performance brands, ATA brands have an established reputation for providing outstanding customer service and a dedication to manufacturing the industry’s highest quality products.”
Harvey Performance and ATA are both established leaders in their respective geographies, and the acquisition is expected to create a powerful combination across North America and Europe. The acquisition will bring an outstanding international platform on which Harvey Performance can continue to grow and expand. The ATA management team will continue to drive business for the company outside of the US.
“This acquisition presents great potential for Harvey Performance,” said Harvey Performance Company Senior Vice President of Sales Jerry Gleisner. “It provides Harvey Performance’s North American customers with exposure to some of the best industrial cutting tools that Europe has to offer.”
Peter Cosgrove, CEO of ATA, said, "ATA is delighted to join Harvey Performance Company, with whom we share a unified global vision for the future. We’re focused on expanding Harvey Performance's brands across Europe and beyond while introducing ATA's leading brands to Harvey Performance’s customers. I am honoured to join the Harvey Performance board. Our management team is looking forward to collaborating with our new colleagues, and our primary focus remains on driving business growth globally.”
“We are excited for the many growth opportunities enabled by the combination of Harvey Performance and ATA’s highly complementary offerings and talented leadership teams,” said Ted Rainaud, Managing Director, Berkshire Partners. “This acquisition represents a significant expansion of Harvey Performance’s product offering and geographic presence. We look forward to supporting the continued growth and expansion of the combined business.”
ATA’s investment partners Development Capital and the Ireland Strategic Investment Fund, who invested in 2017 and 2019 respectively, will exit as a result of the transaction.
Andrew Bourg, Co-founder and Director of Development Capital said, “We are delighted to see ATA attract a company the caliber of Harvey Performance, reflecting the success of the vision for the sector by the ATA management team. During the investment period we have been delighted to help ATA scale significantly and develop into an international leader in the cutting tools industry.”
Brian O’Connor, Ireland Strategic Investment Fund said, “ISIF’s investment in ATA is a clear example of its double bottom line mandate in action, investing on a commercial basis to support the scaling of an Irish indigenous business globally, and so supporting economic activity and the creation of high value employment in Ireland. Today’s announcement reflects a strong performance by the ATA team, a positive outcome for the company and a strong investment return for ISIF.”
Piper Sandler acted as exclusive financial advisor to Harvey Performance Company and Berkshire Partners on the acquisition of ATA. Houlihan Lokey acted as exclusive financial advisor to ATA.
About Harvey Performance Company
Harvey Performance Company strives to offer unique and innovative products to solve the industries’ most challenging machining requirements. Its distinct brands, Harvey Tool, Helical Solutions, Micro 100, Titan USA, CoreHog, and Valor Holemaking serve specialty needs and markets with a shared commitment to delivering high quality products and superior service. The brands offer a broad range of products and services that help support machinists, engineers, and CNC programmers while giving their shops a competitive advantage. Harvey Performance Company has a proud history of doing business the right way – offering fast, friendly service; providing comprehensive product support; and treating customers, suppliers, and shareholders in a way that builds strategic, strong, and enduring relationships. For more information, visit www.harveyperformance.com.
About ATA
ATA is an Irish headquartered manufacturer and supplier of precision cutting tools for industrial leaders around the globe. ATA serves over 7,500 customers in 90 countries. ATA was acquired in 2008 by Peter Cosgrove (CEO) and equity investors. Today the business has operating facilities located across Ireland, Germany, Switzerland, the UK, the Netherlands, and the US, and employs close to 500 people. Its leading brands Karnasch, SGSPRO, ATA Tools, Van Hoorn Carbide, and ITC and Garryson, are recognized as industry leaders throughout Europe. For more information, visit www.atagroup.com.
About Berkshire Partners
Berkshire Partners is a 100% employee-owned, multi-sector specialist investor in private and public equity. The firm’s private equity team invests in well-positioned, growing companies across services & industrials, technology & communications, consumer, and healthcare. Since inception, Berkshire Partners has made more than 150 private equity investments and has a strong history of collaborating with management teams to grow the companies in which it invests. The firm's public equity group, Stockbridge, founded in 2007, manages a concentrated portfolio seeking attractive long-term investments. The firm’s Stockbridge and Private Equity teams frequently collaborate and leverage their collective industry expertise across sectors. For additional information, visit www.berkshirepartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240715286290/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom